Synthesis and preclinical evaluation of novel PET probes for P-glycoprotein function and expression

Journal of Medicinal Chemistry

Volumn 52, Issue 14, 2009, Pages 4524-4532

  Van Waarde, Aren ^a   Ramakrishnan, Nisha K ^a   Rybczynska, Anna A ^a   Elsinga, Philip H ^a   Berardi, Francesco ^b   De Jong, Johan R ^a   Kwizera, Chantal ^a   Perrone, Roberto ^b   Cantore, Mariangela ^b   Sijbesma, Jurgen W A ^a   Dierckx, Rudi A ^a   Colabufo, Nicola A ^b  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^b UNIVERSITY OF BARI   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

CARBON 11; CYCLOSPORIN A; GLYCOPROTEIN P; NAPHTHALENE DERIVATIVE; VERAPAMIL;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; DRUG DISTRIBUTION; DRUG SYNTHESIS; HUMAN; HUMAN CELL; ISOTOPE LABELING; MALE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; PROTEIN EXPRESSION; PROTEIN FUNCTION; RAT;

ANIMALS; BRAIN; CARBON RADIOISOTOPES; DRUG EVALUATION, PRECLINICAL; GENE EXPRESSION REGULATION; ISOQUINOLINES; KINETICS; MALE; P-GLYCOPROTEIN; POSITRON-EMISSION TOMOGRAPHY; RADIOACTIVE TRACERS; RADIOACTIVITY; RATS; RATS, WISTAR; STAINING AND LABELING; TISSUE DISTRIBUTION;

EID: 67650754043     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm900485a     Document Type: Article

References (37)

1. Schinkel, A. H.; Smit, J. J. M.; Van Tellingen, O.; Beijnen, J. H.; Wagenaar, E.; Van Deemter, L.; Mol, C. A. A. M.; Van der Valk, M. A.; Robanus-Maandag, E. C.; Te Riele, H. P. J.; Berns, A. J. M.; Borst, P. Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell 1994, 77, 491-502.
2. Schinkel, A. H.; Wagenaar, E.; Mol, C. A. A. M.; Van Deemter, L. P-Glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs. J. Clin. Invest. 1996, 97, 2517-2524.
3. Bartels, A. L.; Willemsen, A. T.; Kortekaas, R.; De Jong, B. M.; de Vries, R.; de Klerk, O.; van Oostrom, J. C.; Portman, A.; Leenders, K. L. Decreased blood-brain barrier P-glycoprotein function in the progression of Parkinson's disease, PSP, and MSA. J. Neural Transm. 2008, 115, 1001-1009.
4. Kortekaas, R.; Leenders, K. L.; van Oostrom, J. C.; Vaalburg, W.; Bart, J.; Willemsen, A. T.; Hendrikse, N. H. Blood-brain barrier dysfunction in parkinsonian midbrain in vivo. Ann. Neurol. 2005, 57, 176-179.
5. Vogelgesang, S.; Cascorbi, I.; Schroeder, E.; Pahnke, J.; Kroemer, H. K.; Siegmund, W.; Kunert-Keil, C.; Walker, L. C.; Warzok, R. W. Deposition of Alzheimer's beta-amyloid is inversely correlated with P-glycoprotein expression in the brains of elderly nondemented humans. Pharmacogenetics 2002, 12, 535-541.
6. Muller, M. B.; Keck, M. E.; Binder, E. B.; Kresse, A. E.; Hagemeyer, T. P.; Landgraf, R.; Holsboer, F.; Uhr, M. ABCB1 (MDR1)-type P-glycoproteins at the blood-brain barrier modulate the activity of the hypothalamic-pituitary- adrenocortical system: implications for affective disorder. Neuropsychopharmacology 2003, 28, 1991-1999.
7. Thoeringer, C. K.; Wultsch, T.; Shahbazian, A.; Painsipp, E.; Holzer, P. Multidrug-resistance gene 1-type p-glycoprotein (MDR1 p-gp) inhibition by tariquidar impacts on neuroendocrine and behavioral processing of stress. Psychoneuroendocrinology 2007, 32, 1028-1040.
8. Loscher, W.; Potschka, H. Drug resistance in brain diseases and the role of drug efflux transporters. Nat. Rev. Neurosci. 2005, 6, 591-602.
9. Siddiqui, A.; Kerb, R.; Weale, M. E.; Brinkmann, U.; Smith, A.; Goldstein, D. B.; Wood, N. W.; Sisodiya, S. M. Association of multidrug resistance in epilepsy with a polymorphism in the drug-transporter gene ABCB1. N. Engl. J Med. 2003, 348, 1442-1448.
10. Endicott, J. A.; Ling, V. The biochemistry of P-glycoprotein-mediated multidrug resistance. Annu. Rev. Biochem. 1989, 58, 137-171.
11. Varadi, A.; Szakacs, G.; Bakos, E.; Sarkadi, B. P glycoprotein and the mechanism of multidrug resistance. Novartis Found. Symp. 2002, 243, 54-65.
12. Gottesman, M. M.; Fojo, T.; Bates, S. E. Multidrug resistance in cancer: role of ATP-dependent transporters. Nat. Rev. Cancer 2002, 2, 48-58.
13. Lin, J. H. Drug-drug interaction mediated by inhibition and induction of P-glycoprotein. Adv. Drug Delivery Rev. 2003, 55, 53-81.
14. Yu, D. K. The contribution of P-glycoprotein to pharmacokinetic drug-drug interactions. J. Clin. Pharmacol. 1999, 39, 1203-1211.
15. Verschraagen, M.; Koks, C. H.; Schellens, J. H.; Beijnen, J. H. P-glycoprotein system as a determinant of drug interactions: the case of digoxin-verapamil. Pharmacol. Res. 1999, 40, 301-306.
16. Greiner, B.; Eichelbaum, M.; Fritz, P.; Kreichgauer, H. P.; von Richter, O.; Zundler, J.; Kroemer, H. K. The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin. J. Clin. Invest. 1999, 104, 147-153.
17. Sadeque, A. J.; Wandel, C.; He, H.; Shah, S.; Wood, A. J. Increased drug delivery to the brain by P-glycoprotein inhibition. Clin. Pharmacol. Ther. 2000, 68, 231-237.
18. Thuerauf, N.; Fromm, M. F. The role of the transporter P-glycoprotein for disposition and effects of centrally acting drugs and for the pathogenesis of CNS diseases. Eur. Arch. Psychiatry Clin. Neurosci. 2006, 256, 281-286.
19. Colabufo, N. A.; Berardi, F.; Cantore, M.; Perrone, M. G.; Contino, M.; Inglese, C.; Niso, M.; Perrone, R.; Azzariti, A.; Simone, G. M.; Porcelli, L.; Paradiso, A. Small P-gp modulating molecules: SAR studies on tetrahydroisoquinoline derivatives. Bioorg. Med. Chem. 2008, 16, 362-373.
20. Elsinga, P. H.; Franssen, E. J. F.; Hendrikse, N. H.; Fluks, E.; Weemaes, A. M. A.; Van der Graaf, W. T. A.; De Vries, E. G. E.; Visser, G. M.; Vaalburg, W. Carbon-11-labeled daunorubicin and verapamil for probing P-glycoprotein in tumors with PET. J. Nucl. Med. 1996, 37, 1571-1575.
21. Hendrikse, N. H.; Schinkel, A. H.; De Vries, E. G. E.; Fluks, E.; Van der Graaf, W. T. A.; Willemsen, A. T. M.; Vaalburg, W.; Franssen, E. J. F. Complete in vivo reversal of P-glycoprotein pump function in the blood-brain barrier visualized with positron emission tomography. Br. J. Pharmacol. 1998, 124, 1413-1418.
22. 11C]carvedilol reveals P-glycoprotein modulation kinetics. Br. J. Pharmacol. 2005, 145, 1045-1051.
23. 11C-GR218231 as PET tracer for P-glycoprotein. J. Nucl. Med. 2005, 46, 1384-1392.
24. 11C-N-Desmethyl-Loperamide in Monkeys. J. Nucl. Med. 2009, 50, 108-115.
25. 11C] laniquidar as a tracer of P-glycoprotein: radio synthesis and biodistribution in rats. Nucl. Med. Biol. 2009 (in press).
26. 2 activity of a new model of arylpiperazines: 1-aryl-4-[3-(1,2-dihydronaphthalen- 4-yl)-n-propyl]piperazines. 1. Synthesis and structure-activity relationships. J. Med. Chem. 1994, 37, 99-104.
27. 1A receptor of 1-aryl-4-[1-tetralin)-alkyl] piperazines. 2. J. Med. Chem. 1995, 38, 942-949.
28. 11C]verapamil. Appl. Radiat. Isot. 2002, 57, 505-507.
29. 11C-methyl]-(-)-cocaine PET studies in human subjects. J Cereb. Blood Flow Metab. 1990, 10, 740-747.
30. 11C]verapamil measured with PET. Neuroimage 2003, 20, 1775-1782.
31. 11C-verapamil and PET. J. Nucl. Med. 2008, 49, 1328-1335.
32. Hendrikse, N. H.; de Vries, E. G. E.; Eriks, F. L.; van der Graaf, W. T. A.; Hospers, G. A. P.; Willemsen, A. T. M.; Vaalburg, W.; Franssen, E. J. F. A new in vivo method to study P-glycoprotein transport in tumors and the blood-brain barrier. Cancer Res. 1999, 59, 2411-2416.
33. Brady, J. M.; Cherrington, N. J.; Hartley, D. P.; Buist, S. C.; Li, N.; Klaassen, C. D. Tissue distribution and chemical induction of multiple drug resistance genes in rats. Drug Metab. Dispos. 2002, 30, 838-844.
34. Chan, L. M.; Lowes, S.; Hirst, B. H. The ABCs of drug transport in intestine and liver: efflux proteins limiting drug absorption and bioavailability. Eur. J. Pharm. Sci. 2004, 21, 25-51.
35. Taipalensuu, J.; Tavelin, S.; Lazorova, L.; Svensson, A. C.; Artursson, P. Exploring the quantitative relationship between the level of MDR1 transcript, protein and function using digoxin as a marker of MDR1-dependent drug efflux activity. Eur. J. Pharm. Sci. 2004, 21, 69-75.
36. Valenzuela, B.; Nacher, A.; Ruiz-Carretero, P.; Martin-Villodre, A.; Lopez-Carballo, G.; Barettino, D. Profile of P-glycoprotein distribution in the rat and its possible influence on the salbutamol intestinal absorption process. J. Pharm. Sci. 2004, 93, 1641-1648.
37. MacLean, C.; Moenning, U.; Reichel, A.; Fricker, G. Closing the gaps: a full scan of the intestinal expression of p-glycoprotein, breast cancer resistance protein, and multidrug resistance-associated protein 2 in male and female rats. Drug Metab. Dispos. 2008, 36, 1249-1254.2